Dr. Heide Schatten is a cell and molecular biologist at University of Missouri-Columbia. She specializes in reproduction and cancers of the reproductive systems. She has been involved as scientist adviser to advocates of Cancer Foundations and as a reviewer and study section leader of several Foundations and she has been a reviewer for the DOD prostate cancer program. She has had Cancer Research support and interacted with a large number of well known prostate cancer researchers including many from NIH Comprehensive Cancer Centers.  Her publication record shows over 220 original publications, many of which are focused on cell cycle and cytoskeletal abnormalities that are hallmarks for prostate cancer.  She has edited several previous books including (2013) Cell and Molecular Biology of Breast Cancer which has over 19,000 downloads.

• 1. The role of imaging in clinical prostate cancer – Overview of Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Dynamic Contrast-Enhanced MRI (DCE-MRI), MR spectroscopic Imaging (MRSI), Photoacoustic Imaging (PAI).- 2. Automated quantitative cell and tissue imaging technologies.- 3. Diagnostic and early prostate cancer imaging; imaging of advanced prostate cancer.- 4. Emerging radiation techniques.- 5. Radiation therapy and partial prostate irradiation.- 6. Prostate cancer screening: radiology perspectives.- 7. Preclinical imaging of metastasis and dormancy: clinical implications.- 8. Utility of CT in the management of prostate cancer.- 9. Nanotechnology, cancer diagnosis and treatments.- 10. Imaging approaches to distinguish lethal from non-lethal disease.- 11. Photoacoustic imaging.- 12. Molecular and anatomical imaging in drug development.- 13. Molecular imaging modalities including CT, PET, SPECT, MRI, MRS, Hyperpolarized MRI, Ultrasound, X-ray computed tomography, Fusion Imaging (Molecular/Anatomic).- 14. Functional imaging (PET vs. SPECT).- 15. Optical bioluminescence molecular imaging.- 16. Therapeutic radiopharmaceutical translational research imaging.- 17. Accuracy of magnetic resonance imaging for local staging of prostate cancer: diagnostic meta-analysis.- 18. Adjuvant radiotherapy for pathologically advanced prostate cancer: randomized clinical trial.- 19. High-intensity focused ultrasound (HIFU) with histopathological analysis.- 20. Image-directed, tissue-preserving focal therapy of prostate cancer with a novel deformable magnetic resonance-ultrasound (MR-US) registration system.- 21. Focal therapy for localized unifocal and multifocal prostate cancer.- 22. Focal cryotherapy for clinically unilateral, low to intermediate risk prostate cancer.- 23. Impact of obesity on clinico-pathologic outcomes after robot-assisted laparoscopic prostatectomy.- 24. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.

Dr. Heide Schatten is a cell and molecular biologist at University of Missouri-Columbia. She specializes in reproduction and cancers of the reproductive systems. She has been involved as scientist adviser to advocates of Cancer Foundations and as a reviewer and study section leader of several Foundations and she has been a reviewer for the DOD prostate cancer program. She has had Cancer Research support and interacted with a large number of well known prostate cancer researchers including many from NIH Comprehensive Cancer Centers.  Her publication record shows over 220 original publications, many of which are focused on cell cycle and cytoskeletal abnormalities that are hallmarks for prostate cancer.  She has edited several previous books including (2013) Cell and Molecular Biology of Breast Cancer which has over 19,000 downloads.

• 1. The role of imaging in clinical prostate cancer – Overview of Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Dynamic Contrast-Enhanced MRI (DCE-MRI), MR spectroscopic Imaging (MRSI), Photoacoustic Imaging (PAI).- 2. Automated quantitative cell and tissue imaging technologies.- 3. Diagnostic and early prostate cancer imaging; imaging of advanced prostate cancer.- 4. Emerging radiation techniques.- 5. Radiation therapy and partial prostate irradiation.- 6. Prostate cancer screening: radiology perspectives.- 7. Preclinical imaging of metastasis and dormancy: clinical implications.- 8. Utility of CT in the management of prostate cancer.- 9. Nanotechnology, cancer diagnosis and treatments.- 10. Imaging approaches to distinguish lethal from non-lethal disease.- 11. Photoacoustic imaging.- 12. Molecular and anatomical imaging in drug development.- 13. Molecular imaging modalities including CT, PET, SPECT, MRI, MRS, Hyperpolarized MRI, Ultrasound, X-ray computed tomography, Fusion Imaging (Molecular/Anatomic).- 14. Functional imaging (PET vs. SPECT).- 15. Optical bioluminescence molecular imaging.- 16. Therapeutic radiopharmaceutical translational research imaging.- 17. Accuracy of magnetic resonance imaging for local staging of prostate cancer: diagnostic meta-analysis.- 18. Adjuvant radiotherapy for pathologically advanced prostate cancer: randomized clinical trial.- 19. High-intensity focused ultrasound (HIFU) with histopathological analysis.- 20. Image-directed, tissue-preserving focal therapy of prostate cancer with a novel deformable magnetic resonance-ultrasound (MR-US) registration system.- 21. Focal therapy for localized unifocal and multifocal prostate cancer.- 22. Focal cryotherapy for clinically unilateral, low to intermediate risk prostate cancer.- 23. Impact of obesity on clinico-pathologic outcomes after robot-assisted laparoscopic prostatectomy.- 24. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.

Dr. Heide Schatten is a cell and molecular biologist at University of Missouri-Columbia. She specializes in reproduction and cancers of the reproductive systems. She has been involved as scientist adviser to advocates of Cancer Foundations and as a reviewer and study section leader of several Foundations and she has been a reviewer for the DOD prostate cancer program. She has had Cancer Research support and interacted with a large number of well known prostate cancer researchers including many from NIH Comprehensive Cancer Centers.  Her publication record shows over 220 original publications, many of which are focused on cell cycle and cytoskeletal abnormalities that are hallmarks for prostate cancer.  She has edited several previous books including (2013) Cell and Molecular Biology of Breast Cancer which has over 19,000 downloads.

• 1. The role of imaging in clinical prostate cancer – Overview of Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Dynamic Contrast-Enhanced MRI (DCE-MRI), MR spectroscopic Imaging (MRSI), Photoacoustic Imaging (PAI).- 2. Automated quantitative cell and tissue imaging technologies.- 3. Diagnostic and early prostate cancer imaging; imaging of advanced prostate cancer.- 4. Emerging radiation techniques.- 5. Radiation therapy and partial prostate irradiation.- 6. Prostate cancer screening: radiology perspectives.- 7. Preclinical imaging of metastasis and dormancy: clinical implications.- 8. Utility of CT in the management of prostate cancer.- 9. Nanotechnology, cancer diagnosis and treatments.- 10. Imaging approaches to distinguish lethal from non-lethal disease.- 11. Photoacoustic imaging.- 12. Molecular and anatomical imaging in drug development.- 13. Molecular imaging modalities including CT, PET, SPECT, MRI, MRS, Hyperpolarized MRI, Ultrasound, X-ray computed tomography, Fusion Imaging (Molecular/Anatomic).- 14. Functional imaging (PET vs. SPECT).- 15. Optical bioluminescence molecular imaging.- 16. Therapeutic radiopharmaceutical translational research imaging.- 17. Accuracy of magnetic resonance imaging for local staging of prostate cancer: diagnostic meta-analysis.- 18. Adjuvant radiotherapy for pathologically advanced prostate cancer: randomized clinical trial.- 19. High-intensity focused ultrasound (HIFU) with histopathological analysis.- 20. Image-directed, tissue-preserving focal therapy of prostate cancer with a novel deformable magnetic resonance-ultrasound (MR-US) registration system.- 21. Focal therapy for localized unifocal and multifocal prostate cancer.- 22. Focal cryotherapy for clinically unilateral, low to intermediate risk prostate cancer.- 23. Impact of obesity on clinico-pathologic outcomes after robot-assisted laparoscopic prostatectomy.- 24. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.